MoonLake Immunotherapeutics MLTX Increase in accrued expenses and other liabilities
Increase in accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's increase in accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's increase in accrued expenses and other liabilities?
- MoonLake Immunotherapeutics (MLTX) reported increase in accrued expenses and other liabilities of $7.12M in Q1 2026.
- How has MoonLake Immunotherapeutics's increase in accrued expenses and other liabilities changed year-over-year?
- MoonLake Immunotherapeutics's increase in accrued expenses and other liabilities increased by 557.8% year-over-year, from -$1.56M to $7.12M.
- What is the long-term trend for MoonLake Immunotherapeutics's increase in accrued expenses and other liabilities?
- Over 2 years (2021 to 2024), MoonLake Immunotherapeutics's increase in accrued expenses and other liabilities has grown at a -16.1% compound annual growth rate (CAGR), from $7.34M to $5.17M.